NORCROSS, Ga., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing the results of its Phase 2b NASH-CX trial on Tuesday morning, December 5, 2017. The company will host a conference call and webcast, including a slide presentation, beginning at 8:30 a.m. ET on December 5, 2017.
Peter G. Traber, M.D., the company’s CEO and CMO, and Stephen A. Harrison, M.D., one of lead investigators of the NASH-CX trial, medical director of Pinnacle Clinical Research in San Antonio, Texas, and visiting professor of medicine at the University of Oxford, United Kingdom, will present the results in the webcast.
Dial-in information and webcast details are listed below:
Tuesday, December 5, 2017, 8:30 a.m. Eastern Time
Participant Toll Free Dial-In Number: 888-317-6003
Participant International Dial-In Number: 412-317-6061
Conference ID: 3493752
Webcast URL:
https://services.choruscall.com/links/galt171205.html
Callers should dial in approximately 10 minutes before the live call begins.
Dial-in information and webcast details for replay access are listed below. The dial-in replay will be available until Tuesday, Dec 12, 2017. The webcast replay will be archived for one year.
Replay Toll Free Dial-In Number: 877-344-7529
Replay International Dial-In Number: 412-317-0088
Replay Access Code: 10114808
Webcast Replay:
https://services.choruscall.com/links/galt171205.html
The slide presentation will be available via both the webcast and the presentations page of the investor relations portion of Galectin’s website.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts:
Galectin Therapeutics, Inc.
Jack Callicutt, Chief Financial Officer
678-620-3186
ir@galectintherapeutics.com